Black Bird Biotech withdraws three separate convertible notes with cash refunds
FLOWER MOUND, TX / ACCESSWIRE / October 5, 2021 / Black Bird Biotech, Inc. (OTC PINK: BBBT), maker of herbal MiteXstreamMT biopesticide, today announced it has repaid approximately $ 225,000 of the remaining debt under three separate convertible notes with cash payments. BBBT’s decision served to protect shareholders from a potentially large market surplus due to below-market conversion rates.
“We have taken these convertible bonds as a bridge that has enabled us to achieve important milestones, and now we are moving forward with the goal of being debt free by the end of 2021,” said Fabian. Deneault, president of BBBT.
For news and updates, shareholders, potential investors and potential business partners are encouraged to follow @BBBT_Corporate on Twitter (https://twitter.com/BBBT_Corporate). Also visit the BBBT company website, https://blackbirdbiotech.com, for additional company information.
Black Bird Biotech is positioned to tap market segments with powerful and reinvented biotechnology products. Its EPA-approved biopesticide, MiteXstreamMT, eradicates mites and similar parasites, including spider mites (a deadly pest of cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates mold and mildew. MiteXstreamMT is a pesticide, but it’s not a poison – it’s a reimagined pesticide. The MiteXstreamMT Edge: Use throughout harvest day without worrying about residual “pesticide” violations, including in state cannabis testing. MiteXstreamMT is the backbone of the company which has vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional “toxic” pesticides.
This press release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements contained in this press release are Forward-looking statements are not purely historical and include all statements regarding beliefs, plans, expectations or intentions regarding the future, including, but not limited to, the products sold or cash flow from operations.
Actual results could differ from those projected in forward-looking statements due to many factors. These factors include, among others, the uncertainties inherent in distribution and the difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be correct. Investors should consult all information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports and other periodic reports filed from time to time with the Securities and Exchange Commission.
THE SOURCE: Black Bird Biotech, Inc.
See the source version on accesswire.com: